Coexistence of TDP-43 and tau pathology in neurodegeneration with brain iron accumulation type 1 (NBIA-1, formerly Hallervorden-Spatz syndrome)
Corresponding Author
Takashi Haraguchi
Department of Neurology, National Hospital Organization Minami-Okayama Medical Center,
Takashi Haraguchi, MD, PhD, Department of Neurology, National Hospital Organization Minami-Okayama Medical Center, 4066 Hayashima-cho, Tsukubo-gun, Okayama 701-0304, Japan. Email: [email protected]Search for more papers by this authorSeishi Terada
Department of Neuropsychiatry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences,
Search for more papers by this authorHideki Ishizu
Department of Laboratory and Medicine, Zikei Institute, Okayama,
Search for more papers by this authorOsamu Yokota
Department of Neuropsychiatry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences,
Search for more papers by this authorHidenori Yoshida
Department of Neurology, National Hospital Organization Minami-Okayama Medical Center,
Search for more papers by this authorNaoya Takeda
Department of Neuropsychiatry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences,
Search for more papers by this authorYuki Kishimoto
Department of Neuropsychiatry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences,
Search for more papers by this authorNaoko Katayama
Department of Neurology, National Hospital Organization Minami-Okayama Medical Center,
Search for more papers by this authorHiroshi Takata
Department of Neurology, Kinashi Obayashi Hospital, Takamatsu
Search for more papers by this authorMotohiro Akagi
Department of Developmental Medicine (Pediatrics), Osaka University Graduate School of Medicine, Osaka, Japan
Search for more papers by this authorShigetoshi Kuroda
Department of Laboratory and Medicine, Zikei Institute, Okayama,
Search for more papers by this authorYuetsu Ihara
Department of Neurology, National Hospital Organization Minami-Okayama Medical Center,
Search for more papers by this authorYosuke Uchitomi
Department of Neuropsychiatry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences,
Search for more papers by this authorCorresponding Author
Takashi Haraguchi
Department of Neurology, National Hospital Organization Minami-Okayama Medical Center,
Takashi Haraguchi, MD, PhD, Department of Neurology, National Hospital Organization Minami-Okayama Medical Center, 4066 Hayashima-cho, Tsukubo-gun, Okayama 701-0304, Japan. Email: [email protected]Search for more papers by this authorSeishi Terada
Department of Neuropsychiatry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences,
Search for more papers by this authorHideki Ishizu
Department of Laboratory and Medicine, Zikei Institute, Okayama,
Search for more papers by this authorOsamu Yokota
Department of Neuropsychiatry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences,
Search for more papers by this authorHidenori Yoshida
Department of Neurology, National Hospital Organization Minami-Okayama Medical Center,
Search for more papers by this authorNaoya Takeda
Department of Neuropsychiatry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences,
Search for more papers by this authorYuki Kishimoto
Department of Neuropsychiatry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences,
Search for more papers by this authorNaoko Katayama
Department of Neurology, National Hospital Organization Minami-Okayama Medical Center,
Search for more papers by this authorHiroshi Takata
Department of Neurology, Kinashi Obayashi Hospital, Takamatsu
Search for more papers by this authorMotohiro Akagi
Department of Developmental Medicine (Pediatrics), Osaka University Graduate School of Medicine, Osaka, Japan
Search for more papers by this authorShigetoshi Kuroda
Department of Laboratory and Medicine, Zikei Institute, Okayama,
Search for more papers by this authorYuetsu Ihara
Department of Neurology, National Hospital Organization Minami-Okayama Medical Center,
Search for more papers by this authorYosuke Uchitomi
Department of Neuropsychiatry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences,
Search for more papers by this authorAbstract
We report here an autopsy case of sporadic adult-onset Hallervorden-Spatz syndrome, also known as neurodegeneration with brain iron accumulation type 1 (NBIA1), without hereditary burden. A 49-year-old woman died after a 27-year disease course. At the age of 22, she suffered from akinesia, resting tremor, and rigidity. At the age of 28, she was admitted to our hospital because of worsening parkinsonism and dementia. Within several years, she developed akinetic mutism. At the age of 49, she died of bleeding from a tracheostomy. Autopsy revealed a severely atrophic brain weighing 460 g. Histologically, there were iron deposits in the globus pallidus and substantia nigra pars reticulata, and numerous axonal spheroids in the subthalamic nuclei. Neurofibrillary tangles were abundant in the hippocampus, cerebral neocortex, basal ganglia, and brain stem. Neuritic plaques and amyloid deposits were absent. Lewy bodies and Lewy neurites, which are immunolabeled by anti-α-synuclein, were absent. We also observed the presence of TDP-43-positive neuronal perinuclear cytoplasmic inclusions, with variable frequency in the dentate gyrus granular cells, frontal and temporal cortices, and basal ganglia. TDP-43-positive glial cytoplasmic inclusions were also found with variable frequency in the frontal and temporal lobes and basal ganglia. The present case was diagnosed with adult-onset NBIA-1 with typical histological findings in the basal ganglia and brainstem. However, in this case, tau and TDP-43 pathology was exceedingly more abundant than α-synuclein pathology. This case contributes to the increasing evidence for the heterogeneity of NBIA-1.
REFERENCES
- 1 Taylor TD, Litt M, Kramer P et al. Homozygosity mapping of Hallervorden-Spatz syndrome to chromosome 20p12.3-p13. Nat Genet 1996; 14: 479–481.
- 2 Jellinger KA, Dura J. Neurodegeneration with brain iron accumulation, type 1 (Hallervorden-Spatz disease). In: D Dickson, ed. Pathology & Genetics: Neurodegenerative Diseases. Basel: ISN Neuropath Press, 2003; 394–399.
- 3 Arawaka S, Saito Y, Murayama S, Mori H. Lewy body in neurodegeneration with brain iron accumulation type 1 is immunoreactive for alpha-synuclein. Neurology 1998; 51: 887–889.
- 4 Zhou B, Westaway SK, Levinson B, Johnson MA, Gitschier J, Hayflick SJ. A novel pantothenate kinase gene (PANK2) is defective in Hallervorden-Spatz syndrome. Nat Genet 2001; 28: 345–349.
- 5 Gordon N. Pantothenate kinase-associated neurodegeneration (Hallervorden-Spatz syndrome). Eur J Paediatr Neurol 2002; 6: 243–247.
- 6 Dooling EC, Schoene WC, Richardson EP Jr. Hallervorden-Spatz syndrome. Arch Neurol 1974; 30: 70–83.
- 7 Jellinger K. Neuroaxonal dystrophy: its natural history and related disorders. In: H Zimmerman, ed. Progress in Neuropathology, Vol. 2. New York: Grune and Stratton, 1973; 129–180.
- 8 Park BE, Netsky MG, Betsill WL Jr. Pathogenesis of pigment and spheroid formation in Hallervorden-Spatz syndrome and related disorders. Neurology 1975; 25: 1172–1178.
- 9 Fuse S, Inoue K, Iwata M, Mannen T, Toyokura Y. An autopsy case of Hallervorden-Spatz disease with protracted course of about 30 years (in Japanese with English abstract). Neurol Med (Tokyo) 1987; 27: 155–167.
- 10 Newell KL, Boyer P, Gomez-Tortosa E et al. Alpha-synuclein immunoreactivity is present in axonal swellings in neuroaxonaldystrophy and acute traumatic brain injury. J Neuropathol Exp Neurol 1999; 58: 1263–1268.
- 11 Wakabayashi K, Yoshimoto M, Fukushima T et al. Widespread occurrence of alpha-synuclein/NACP-immunoreactive neuronal inclusions in juvenile and adult-onset Hallervorden-Spatz disease with Lewy bodies. Neuropathol Appl Neurobiol 1999; 25: 363–368.
- 12 Neumann M, Adler S, Schluter O, Kremmer E, Benecke R, Kretzschmar HA. Alpha-synuclein accumulation in a case of neurodegeneration with brain iron accumulation type 1 (NBIA-1, formerly Hallervorden-Spatz syndrome) with widespread cortical and brainstem-type Lewy bodies. Acta Neuropathol (Berl) 2000; 100: 568–574.
- 13 Wakabayashi K, Fukushima T, Koide R et al. Juvenile-onset generalized neuroaxonal dystrophy (Hallervorden-Spatz disease) with diffuse neurofibrillary and lewy body pathology. Acta Neuropathol (Berl) 2000; 99: 331–336.
- 14 Saito Y, Kawai M, Inoue K et al. Widespread expression of alpha-synuclein and tau immunoreactivity in Hallervorden-Spatz syndrome with protracted clinical course. J Neurol Sci 2000; 177: 48–59.
- 15 Zarranz JJ, Gómez-Esteban JC, Atarés B, Lezcano E, Forcadas M. Tau-predominant-associated pathology in a sporadic late-onset Hallervorden-Spatz syndrome. Mov Disord 2006; 21: 107–111.
- 16 Tu PH, Galvin JE, Baba M et al. Glial cytoplasmic inclusions in white matter oligodendrocytes of multiple system atrophy brains contain insoluble alpha-synuclein. Ann Neurol 1998; 44: 415–422.
- 17 Wisniewski K, Jervis GA, Moretz RC, Wisniewski HM. Alzheimer neurofibrillary tangles in diseases other than senile and presenile dementia. Ann Neurol 1979; 5: 288–294.
- 18 Hartmann HA, White SK, Levine RL. Neuroaxonal dystrophy with neuromelanin deposition, neurofibrillary tangles, and neuronal loss: light- and electron-microscopic changes in a 45-year-old woman with progressive psychomotor deterioration. Acta Neuropathol (Berl) 1983; 61: 169–172.
- 19 Eidelberg D, Sotrel A, Joachim C et al. Adult onset Hallervorden-Spatz disease with neurofibrillary pathology: a discrete clinicopathological entity. Brain 1987; 110: 993–1013.
- 20 Yamamoto T, Kawamura J, Hashimoto S et al. Pallido-nigro-luysian atrophy, progressive supranuclear palsy and adult onset Hallervorden-Spatz disease: a case of akinesia as a predominant feature of Parkinsonism. J Neurol Sci 1991; 101: 98–106.
- 21
Takada K.
Early occurrence of Alzheimer's neurofibrillary tangles (NFT) in developmental brain damage and chronic brain diseases with early childhood onset.
Neuropathology
1993; 13: 333–335.
10.1111/j.1440-1789.1993.tb00217.x Google Scholar
- 22 Halliday W. The nosology of Hallervorden-spatz disease. J Neurol Sci 1995; 134 (Suppl): 84–91.
- 23 Grimes DA, Lang AE, Bergeron C. Late adult onset chorea with typical pathology of Hallervorden-Spatz syndrome. J Neurol Neurosurg Psychiatry 2000; 69: 392–395.
- 24 Gaytan-Garcia S, Kaufmann JC, Young GB. Adult onset Hallervorden-Spatz syndrome or Seitelberger's disease with late onset: variants of the same entity? A clinico-pathological study. Clin Neuropathol 1990; 9: 136–142.
- 25 Hayashi S, Akasaki Y, Morimura Y, Takauchi S, Sato M, Miyoshi K. An autopsy case of late infantile and juvenile neuroaxonal dystrophy with diffuse Lewy bodies and neurofibrillary tangles. Clin Neuropathol 1992; 11: 1–5.
- 26 Neumann M, Sampathu DM, Kwong LK et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 2006; 314: 130–133.
- 27 Nakashima-Yasuda H, Uryu K, Robinson J et al. Co-morbidity of TDP-43 proteinopathy in Lewy body related diseases. Acta Neuropathol 2007; 114: 221–229.
- 28 Geser F, Winton MJ, Kwong LK et al. Pathological TDP-43 in parkinsonism-dementia complex and amyotrophic lateral sclerosis of Guam. Acta Neuropathol 2008; 115: 133–145.
- 29 Hasegawa M, Arai T, Akiyama H et al. TDP-43 is deposited in the Guam parkinsonism-dementia complex brains. Brain 2007; 130: 1386–1394.
- 30 Uryu K, Nakashima-Yasuda H, Forman MS et al. Concomitant TAR-DNA-binding protein 43 pathology is present in Alzheimer disease and corticobasal degeneration but not in other tauopathies. J Neuropathol Exp Neurol 2008; 67: 555–564.
- 31 Kadokura A, Yamazaki T, Lemere CA, Takatama M, Okamoto K. Regional distribution of TDP-43 inclusions in Alzheimer disease (AD) brains: their relation to AD common pathology. Neuropathology 2009; 29: 566–573.
- 32 Racette BA, Perry A, D'Avossa G, Perlmutter JS. Late-onset neurodegeneration with brain iron accumulation type 1: expanding the clinical spectrum. Mov Disord 2001; 16: 1148–1152.
- 33 Forman MS, Mackenzie IR, Cairns NJ et al. Novel ubiquitin neuropathology in frontotemporal dementia with valosin-containing protein gene mutations. J Neuropathol Exp Neurol 2006; 65: 571–581.
- 34 Mackenzie IR, Baborie A, Pickering-Brown S et al. Heterogeneity of ubiquitin pathology in frontotemporal lobar degeneration: classification and relation to clinical phenotype. Acta Neuropathol (Berl) 2006; 112: 539–549.
- 35 Sampathu DM, Neumann M, Kwong LK et al. Pathological heterogeneity of frontotemporal lobar degeneration with ubiquitin-positive inclusions delineated by ubiquitin immunohistochemistry and novel monoclonal antibodies. Am J Pathol 2006; 169: 1343–1352.
- 36 Cairns NJ, Bigio EH, Mackenzie IR et al. Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the Consortium for Frontotemporal Lobar Degeneration. Acta Neuropathol (Berl) 2007; 114: 5–22.
- 37 Amador-Ortiz C, Lin WL, Ahmed Z et al. TDP-43 immunoreactivity in hippocampal sclerosis and Alzheimer's disease. Ann Neurol 2007; 61: 435–445.
- 38 Higashi S, Iseki E, Yamamoto R et al. Concurrence of TDP-43, tau and alpha-synuclein pathology in brains of Alzheimer's disease and dementia with Lewy bodies. Brain Res 2007; 1184: 284–294.
- 39 Schwab C, Arai T, Hasegawa M, Yu S, McGeer PL. Colocalization of TDP-43 and huntingtin in inclusions of Huntington's disease. J Neuropathol Exp Neurol 2008; 67: 1159–1165.
- 40 Rozdilsky B, Bolton CF, Takeda M. Neuroaxonal dystrophy: a case of delayed onset and protracted course. Acta Neuropathol (Berl) 1971; 17: 331–340.
- 41 Hayflick SJ, Westaway SK, Levinson B et al. Genetic, clinical, and radiographic delineation of Hallervorden-Spatz syndrome. N Engl J Med 2003; 348: 33–40.
- 42 Thomas M, Hayflick SJ, Jankovic J. Clinical heterogeneity of neurodegeneration with brain iron accumulation (Hallervorden-Spatz syndrome) and pantothenate kinase-associated neurodegeneration. Mov Disord 2004; 19: 36–42.
- 43 Koeppen AH, Dickson AC. Iron in the Hallervorden-Spatz syndrome. Pediatr Neurol 2001; 25: 148–155.